Syros Pharmaceuticals (SYRS) PT Set at $28.00 by Oppenheimer
A number of other equities analysts have also commented on SYRS. Cann reissued a buy rating and issued a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Zacks Investment Research lowered shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. Cowen reissued a buy rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. JMP Securities raised shares of Syros Pharmaceuticals from a market perform rating to an outperform rating and set a $33.00 price target on the stock in a research report on Thursday, September 28th. Finally, ValuEngine lowered shares of Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, September 22nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average price target of $26.14.
Syros Pharmaceuticals (NASDAQ SYRS) opened at $8.99 on Wednesday. Syros Pharmaceuticals has a 52-week low of $6.30 and a 52-week high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings results on Wednesday, November 8th. The company reported ($0.53) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.53). equities analysts expect that Syros Pharmaceuticals will post -2.12 earnings per share for the current year.
In related news, Director Srinivas Akkaraju acquired 109,774 shares of the stock in a transaction dated Thursday, December 14th. The shares were acquired at an average price of $9.03 per share, for a total transaction of $991,259.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the stock in a transaction dated Friday, December 15th. The stock was bought at an average price of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of Syros Pharmaceuticals in the third quarter worth $240,000. Cubist Systematic Strategies LLC acquired a new stake in Syros Pharmaceuticals during the third quarter worth $149,000. Schwab Charles Investment Management Inc. boosted its stake in Syros Pharmaceuticals by 95.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 41,709 shares of the company’s stock worth $614,000 after buying an additional 20,409 shares in the last quarter. Citadel Advisors LLC acquired a new stake in Syros Pharmaceuticals during the third quarter worth $975,000. Finally, Trexquant Investment LP acquired a new stake in Syros Pharmaceuticals during the third quarter worth $282,000. Institutional investors and hedge funds own 58.02% of the company’s stock.
WARNING: “Syros Pharmaceuticals (SYRS) PT Set at $28.00 by Oppenheimer” was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/syros-pharmaceuticals-syrs-pt-set-at-28-00-by-oppenheimer/1768867.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.